Beta Bionics (BBNX) CCO Mark Hopman Sells 36,870 Shares

What Happened
Mark Hopman, Chief Commercial Officer of Beta Bionics, sold 36,870 shares on September 9, 2026 at $18.46 per share, generating proceeds of $680,723. The sale is reported as a disposition (code S) and was executed pursuant to a Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-09-09; reported on Form 4 filed 2026-09-10 (timely filing).
• Price and size: 36,870 shares at $18.46 per share; total proceeds $680,723.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote: F1 — sale executed pursuant to a Rule 10b5-1 plan adopted June 10, 2026 (pre‑planned trade).
• Transaction code: S (sale / disposition).

Context
Sales made under a Rule 10b5-1 plan are pre-arranged and often routine; they do not by themselves indicate a change in the insider’s view of the company. For retail investors, purchases generally carry more direct signal value than routine, plan-based sales.